Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.55 |
| ▸ | FNTB | P49356 | 8/20 | 0.55 |
| ▸ | RORC | P51449 | 9/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373631 | 0.90 | FNTA (0.59) | FNTAFNTBRORC | |
| SCHEMBL4376754 | 0.84 | FNTA (0.54) | FNTAFNTBRORC | |
| SCHEMBL4373656 | 0.81 | FNTA (0.82) | FNTAFNTBRORC | |
| SCHEMBL4370392 | 0.81 | FNTA (0.57) | FNTAFNTBRORC | |
| SCHEMBL4382829 | 0.79 | FNTA (0.62) | FNTAFNTBRORC | |
| SCHEMBL4376761 | 0.79 | FNTA (0.43) | FNTAFNTB | |
| SCHEMBL3554724 | 0.77 | FNTA (0.50) | FNTAFNTBRORC | |
| SCHEMBL4375957 | 0.77 | FNTA (0.58) | FNTAFNTBRORC | |
| SCHEMBL4375776 | 0.77 | FNTA (0.65) | FNTAFNTBRORC | |
| SCHEMBL1683552 | 0.73 | FNTA (0.49) | FNTAFNTBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339709-B1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | disclosed |
| US-7153958-B2 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-26 | — | — | US | disclosed |
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1339709-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042296-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885RORC 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.